Nimbus Therapeutics, Gilead deal

Gilead will acquire the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics for $400 million up front and up to $800 million in development milestones. The deal gives Gilead a portfolio of acetyl-coenzyme A carboxylase ( ACAC; ACC) inhibitors for liver diseases, including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Data from a Phase I study of lead program NDI-010976 will be presented next month at the European Association for the Study of the Liver (EASL) meeting. The rest of the assets are in preclinical development. ...